VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Saturday, January 10, 2026
Stock Comparison
BlackRock, Inc. vs Vertex Pharmaceuticals Incorporated
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
BlackRock, Inc.
BLK · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into BlackRock, Inc.'s moat claims, evidence, and risks.
View BLK analysisVertex Pharmaceuticals Incorporated
VRTX · NASDAQ
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Vertex Pharmaceuticals Incorporated's moat claims, evidence, and risks.
View VRTX analysisComparison highlights
- Moat score gap: Vertex Pharmaceuticals Incorporated leads (99 / 100 vs 59 / 100 for BlackRock, Inc.).
- Segment focus: BlackRock, Inc. has 7 segments (33% in iShares ETFs & ETPs); Vertex Pharmaceuticals Incorporated has 3 segments (99.9% in Cystic Fibrosis CFTR Modulators).
- Primary market structure: Oligopoly vs Quasi-Monopoly. Pricing power: Moderate vs Strong.
- Moat breadth: BlackRock, Inc. has 10 moat types across 2 domains; Vertex Pharmaceuticals Incorporated has 7 across 4.
Primary market context
BlackRock, Inc.
iShares ETFs & ETPs
Exchange-traded funds (ETFs) and exchange-traded products (ETPs)
Global
Institutional and retail (via intermediaries)
ETF sponsor / asset manager
33%
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis CFTR Modulators
CFTR modulator therapies for cystic fibrosis
U.S., Europe, Australia, Canada
Patients (via specialty pharmacies/payers); CF care centers
Drug developer/manufacturer
99.9%
Side-by-side metrics
Moat coverage
Shared moat types
BlackRock, Inc. strengths
Vertex Pharmaceuticals Incorporated strengths
Segment mix
BlackRock, Inc. segments
Full profile >iShares ETFs & ETPs
Oligopoly
Institutional Index Mandates (Non-ETF)
Oligopoly
Active & Multi-Asset (Public Markets)
Competitive
Alternatives & Private Markets
Oligopoly
Cash Management (MMFs & cash solutions)
Competitive
Aladdin & Technology Services
Oligopoly
Distribution & Advisory Services
Competitive
Vertex Pharmaceuticals Incorporated segments
Full profile >Cystic Fibrosis CFTR Modulators
Quasi-Monopoly
Hemoglobinopathies Gene Therapy (CASGEVY)
Oligopoly
Acute Pain (JOURNAVX)
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listLooking for expansion-stage stocks?
Proven models entering the expansion stage with unit economics that work.
View expansion-stage stocksCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.